Docoh
Loading...

HOOK Hookipa Pharma

News

From Benzinga Pro
12 Health Care Stocks Moving In Friday's Intraday Session
21 Jan 22
Intraday Update, Markets, Movers
HOOKIPA Announces First Patient Enrolled In Phase 2 Trial Evaluating HB-200 And Pembrolizumab For Treatment Of Head And Neck Cancer And Reports FDA's Fast Track Designation
18 Jan 22
Biotech, News, FDA, General
HOOKIPA Pharma Inc. (NASDAQ:HOOK, &lsquo, HOOKIPA', )))), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, announced that the first patient has been dosed with
Stocks That Hit 52-Week Lows On Wednesday
12 Jan 22
News, Options, Intraday Update, Markets, Movers, Trading Ideas
On Wednesday, 41 stocks made new 52-week lows.
Stocks That Hit 52-Week Lows On Thursday
6 Jan 22
News, Options, Intraday Update, Markets, Movers, Trading Ideas
On Thursday, 615 stocks hit new 52-week lows.
Stocks Hitting New 52-Week Lows Today
3 Jan 22
News, Intraday Update, Markets, Movers, Trading Ideas
On Monday morning, 60 companies achieved new lows for the year.
Benzinga's Top Ratings Upgrades, Downgrades For November 12, 2021
12 Nov 21
Upgrades, Downgrades, Initiation, Intraday Update, Analyst Ratings
Morgan Stanley Downgrades HOOKIPA Pharma to Equal-Weight, Announces $6 Price Target
12 Nov 21
News, Downgrades, Price Target, Analyst Ratings
Morgan Stanley analyst Vikram Purohit downgrades HOOKIPA Pharma (NASDAQ:HOOK) from Overweight to Equal-Weight and announces $6 price target.
What 5 Analyst Ratings Have To Say About HOOKIPA Pharma
11 Nov 21
Analyst Ratings
HOOKIPA Pharma (NASDAQ:HOOK) has observed the following analyst ratings within the last quarter:
HOOKIPA Pharma's Return On Capital Employed Insights
11 Nov 21
Earnings
Benzinga Pro data, HOOKIPA Pharma (NASDAQ:HOOK) reported Q3 sales of $3.87 million. Earnings fell to a loss of $21.17 million, resulting in a 9.73% decrease from last quarter.
HC Wainwright & Co. Maintains Buy on HOOKIPA Pharma, Lowers Price Target to $15
11 Nov 21
News, Price Target, Analyst Ratings
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains HOOKIPA Pharma (NASDAQ:HOOK) with a Buy and lowers the price target from $21 to $15.
12 Health Care Stocks Moving In Wednesday's Intraday Session
10 Nov 21
Intraday Update, Markets, Movers
SVB Leerink Maintains Outperform on HOOKIPA Pharma, Lowers Price Target to $10
10 Nov 21
News, Price Target, Analyst Ratings
SVB Leerink analyst Andrew Berens maintains HOOKIPA Pharma (NASDAQ:HOOK) with a Outperform and lowers the price target from $28 to $10.
RBC Capital Maintains Outperform on HOOKIPA Pharma, Lowers Price Target to $17
10 Nov 21
News, Price Target, Analyst Ratings
RBC Capital analyst Brian Abrahams maintains HOOKIPA Pharma (NASDAQ:HOOK) with a Outperform and lowers the price target from $24 to $17.
The Daily Biotech Pulse: Valneva Inks COVID-19 Vaccine Supply Contract In Europe, I-Mab Spikes On China Deal, DermTech Sinks On Guidance
10 Nov 21
Biotech, Earnings, News, Penny Stocks, Guidance, Offerings, Small Cap, FDA, General
Here's a roundup of top developments in the biotech space over the last 24 hours.
JMP Securities Maintains Market Outperform on HOOKIPA Pharma, Lowers Price Target to $11
10 Nov 21
News, Price Target, Analyst Ratings
JMP Securities analyst Jason Butler maintains HOOKIPA Pharma (NASDAQ:HOOK) with a Market Outperform and lowers the price target from $25 to $11.
HOOKIPA Pharma Q3 EPS $(0.61) Misses $(0.52) Estimate, Sales $3.87M Miss $5.72M Estimate
10 Nov 21
Earnings, News
HOOKIPA Pharma (NASDAQ:HOOK) reported quarterly losses of $(0.61) per share which missed the analyst consensus estimate of $(0.52) by 17.31 percent. This is a 15.09 percent decrease over losses of $(0.53) per share from
Earnings Scheduled For November 10, 2021
10 Nov 21
Earnings, News, Pre-Market Outlook, Markets
Companies Reporting Before The Bell • LumiraDx (NASDAQ:LMDX) is projected to report quarterly loss at $0.24 per share on revenue of $94.32 million.
HOOKIPA Advances HB-200 Program To Phase 2 And Prioritizes Oncology Portfolio Based On Clinical Data Updates Across Its Novel Arenaviral Platform
9 Nov 21
News
Based on positive interim Phase 1 data, HOOKIPA initiates Phase 2 study to assess HB-201 in combination with pembrolizumab in 1st and 2nd line head and neck cancer Interim Phase 1 HB-200 data
Preview: HOOKIPA Pharma's Earnings
9 Nov 21
Earnings
HOOKIPA Pharma (NASDAQ:HOOK) is set to give its latest quarterly earnings report on Wednesday, 2021-11-10. Here's what investors need to know before the announcement. Analysts estimate that HOOKIPA Pharma will likely report an Earnings Per Share (EPS) of $-0.52

Press releases

From Benzinga Pro
HOOKIPA Pharma to Present at the H.C. Wainwright BioConnect Conference
4 Jan 22
News, Press Releases
NEW YORK and VIENNA, Austria, Jan. 04, 2022 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ:HOOK, ‘HOOKIPA')), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today
HOOKIPA Pharma to Participate in the JMP Securities Hematology and Oncology Summit
3 Dec 21
News, Press Releases
NEW YORK and VIENNA, Austria, Dec. 03, 2021 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ:HOOK, ‘HOOKIPA')), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today
HOOKIPA Pharma to Participate in Upcoming Stifel 2021 Virtual Healthcare Conference
12 Nov 21
News, Press Releases
NEW YORK and VIENNA, Austria, Nov. 12, 2021 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ:HOOK, ‘HOOKIPA')), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today
HOOKIPA Pharma Reports Third Quarter 2021 Financial Results and Recent Highlights
10 Nov 21
Earnings, Press Releases
Clinical collaboration with Merck & Co., Inc., Kenilworth, NJ, USA, set to evaluate HB-201 in combination with pembrolizumab in 1st- and 2nd-line HNSCC patientsBased on recent strong data updates, HOOKIPA advancing
HOOKIPA advances HB-200 program to Phase 2 and prioritizes oncology portfolio based on clinical data updates across its novel arenaviral platform
9 Nov 21
Press Releases, General
Based on positive interim Phase 1 data, HOOKIPA initiates Phase 2 study to assess HB-201 in combination with pembrolizumab in 1st and 2nd line head and neck cancerInterim Phase 1 HB-200 data continue to show high levels
HOOKIPA Pharma to Report Third Quarter 2021 Financial Results on Wednesday, November 10, 2021
3 Nov 21
News, Press Releases
NEW YORK and VIENNA, Austria, Nov. 03, 2021 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ:HOOK, ‘HOOKIPA')), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today